Learning from the first: a qualitative study of the psychosocial benefits and treatment burdens of long‐acting cabotegravir/rilpivirine among early adopters in three U.S. clinics

Abstract

CAB/RPV-LA offers a range of logistical, psychosocial and care engagement benefits, which are experienced maximally by PWH initiating with viraemia due to adherence challenges; however, benefits do not always outweigh treatment burdens and can result in discontinuation. Our findings on rationales for persistence versus discontinuation can inform both initial and follow-up patient counselling.